Lilly Pays Up to $2.875 Billion for Merida Biosciences to Attack Autoimmune Disease at the Antibody Level
The all-cash deal buys a phase I platform of engineered proteins that target the rogue antibodies driving Graves' disease and thyroid eye disease, with the bulk of the price tied to milestones.
What Happened
Eli Lilly has entered a definitive agreement to acquire Merida Biosciences, a Massachusetts-based clinical-stage biotech, for up to $2.875 billion in cash, the company announced on 31 August. The consideration comprises an upfront payment plus additional amounts contingent on development and regulatory milestones, though neither party disclosed the split.
Merida’s platform engineers proteins that target the pathogenic antibodies underlying autoimmune and allergic diseases, rather than broadly suppressing the immune system. Its lead candidate, MER511, is in phase I development for Graves’ disease and thyroid eye disease. Lilly said the acquisition adds both the antibody-engineering platform and a pipeline of biologics aimed at a range of immune-mediated conditions. Closing is expected in the fourth quarter of 2026, subject to regulatory approvals.
The announcement landed on the same day as Aon’s $17 billion purchase of USI and capped a month in which large pharmaceutical groups continued to pay up for early-stage immunology assets. Lilly has been among the most active acquirers in the sector, and the Merida structure (modest disclosed upfront, large contingent tail) mirrors how it has approached other pre-proof-of-concept deals.
Why It Matters
Lilly is spending obesity profits on immunology optionality. With its metabolic franchise generating enormous cash flow, Lilly has been methodically buying early-stage assets in adjacent areas. Immunology is a large, chronic-disease market dominated by broad immunosuppressants; a platform that removes specific disease-causing antibodies while leaving the rest of the immune system intact would be a genuine mechanistic advance.
The milestone-heavy structure caps the downside. Paying “up to” $2.875 billion for a phase I asset is aggressive on the headline but disciplined in practice. Much of the value is only released if MER511 and its successors clear clinical and regulatory hurdles, which shifts risk back onto the sellers and reflects how early the science still is.
Thyroid eye disease is a proven commercial target. The indication already supports a multibillion-dollar biologic market, which gives Lilly a clear path to revenue if MER511’s approach works. Graves’ disease, a far larger patient population with limited targeted options, is the bigger prize.
- Clinical attrition: Phase I assets fail more often than they succeed; the platform thesis depends on early data holding up in larger trials.
- Competitive crowding: Thyroid eye disease already has established biologics, so MER511 must demonstrate differentiated efficacy or safety to win share.
- Integration of a small team: Preserving the scientific culture of a clinical-stage biotech inside a pharma giant is a recurring challenge.
- Novel mechanism: Targeting pathogenic antibodies directly could offer better tolerability than broad immunosuppression across many indications.
- Platform leverage: Lilly gains an engineering toolkit applicable well beyond the lead asset, multiplying the value of a single acquisition.
- Risk-shared pricing: The milestone structure means Lilly pays full price only for success.
Source: Eli Lilly